Security record · archived quarter
SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
8Tracked holders
—Δ holders
1.67MShares held
$14.24MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.20M | — | $10.18M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.20M | — | $10.18M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 124.10K | — | $1.06M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 116.88K | — | $994,674 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 116.88K | — | $994,674 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 90.76K | — | $772,351 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 68.23K | — | $580,663 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 68.23K | — | $580,663 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 46.92K | — | $399,323 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 15.72K | — | $134,000 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Arrowstreet Capital ✦ | 14.97K | — | $127,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 201 holders, 92.94M shares, $730.00M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API